• AlzeCure Foundation formed.
  • AstraZeneca decides to focus its internal development on CNS candidates in late clinical development phases.
  • AlzeCure’s current management team is offered the opportunity to further develop innovative therapies for Alzheimer’s and related diseases in the recently started AlzeCure Foundation.


  • The foundation begins research and development at the Karolinska Institutet Science Park in Solna.


  • AlzeCure Pharma was founded due to the great commercial potential of the main drug candidates. NeuroRestore is the outcome of in-house research, while Alzstatin derives from AstraZeneca’s research portfolio, where the project was begun on the initiative of AlzeCure’s scientists.


  • In June, the company carried out its first financing round in the amount of SEK 70 million before issue expenses.


  • In July, the company carried out its second financing round in the amount of SEK 40 million aimed at financing phase I studies for ACD855.
  • Preclinical testing of ACD855 was concluded in July.
  • IMPD (application to commence studies in humans) for ACD855 submitted in October.
  • Listing takes place on Nasdaq First North Premier in November.
  • The necessary public authority approvals to begin phase I studies for ACD855 were granted and the company began dosing the first subjects in December.


  • In March, the company initiated a new drug project in the field of pain – TrkA-NAM.
  • In May, the company chose to redirect the drug candidate ACD855 from cognitive dysfunction to an eye indication and ACD856 is now the primary drug candidate for cognitive dysfunction.
  • At the annual general meeting on May 22, 2019, the company resolved to issue a share options program targeted at the company’s Board of Directors.